Basaglar Follow-On Insulin Booms For Eli Lilly

 
• By Aidan Fry

Lilly’s Basaglar insulin glargine hybrid is well on its way to becoming a billion-dollar blockbuster.

DollarsGraph
Rapid volume uptake in the US is pushing Eli Lilly's Basaglar follow-on insulin towards blockbuster status • Source: Shutterstock

More from Earnings

More from Business